Inhibikase Therapeutics (IKT) Competitors $2.37 -0.02 (-0.84%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$2.30 -0.07 (-2.95%) As of 03/27/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IKT vs. CRMD, IMNM, ABUS, BCYC, DNTH, KURA, CDXC, KALV, MGTX, and VALNShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include CorMedix (CRMD), Immunome (IMNM), Arbutus Biopharma (ABUS), Bicycle Therapeutics (BCYC), Dianthus Therapeutics (DNTH), Kura Oncology (KURA), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), MeiraGTx (MGTX), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. CorMedix Immunome Arbutus Biopharma Bicycle Therapeutics Dianthus Therapeutics Kura Oncology ChromaDex KalVista Pharmaceuticals MeiraGTx Valneva Inhibikase Therapeutics (NYSE:IKT) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking. Do analysts rate IKT or CRMD? Inhibikase Therapeutics presently has a consensus price target of $6.50, suggesting a potential upside of 174.26%. CorMedix has a consensus price target of $15.14, suggesting a potential upside of 125.68%. Given Inhibikase Therapeutics' higher possible upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50CorMedix 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media refer more to IKT or CRMD? In the previous week, CorMedix had 28 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 29 mentions for CorMedix and 1 mentions for Inhibikase Therapeutics. CorMedix's average media sentiment score of 0.47 beat Inhibikase Therapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 5 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, IKT or CRMD? Inhibikase Therapeutics has higher earnings, but lower revenue than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase Therapeutics$260K632.26-$19.03M-$2.67-0.89CorMedix$43.47M9.37-$46.34M-$0.33-20.33 Is IKT or CRMD more profitable? CorMedix's return on equity of -79.21% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% CorMedix N/A -79.21%-64.68% Which has more risk and volatility, IKT or CRMD? Inhibikase Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Does the MarketBeat Community believe in IKT or CRMD? CorMedix received 22 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 81.82% of users gave Inhibikase Therapeutics an outperform vote while only 79.49% of users gave CorMedix an outperform vote. CompanyUnderperformOutperformInhibikase TherapeuticsOutperform Votes981.82% Underperform Votes218.18%CorMedixOutperform Votes3179.49% Underperform Votes820.51% Do insiders and institutionals hold more shares of IKT or CRMD? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 4.6% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 5.2% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCorMedix beats Inhibikase Therapeutics on 13 of the 18 factors compared between the two stocks. Remove Ads Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$164.39M$3.04B$5.65B$19.62BDividend YieldN/A1.54%4.57%3.75%P/E Ratio-0.8929.2923.1433.60Price / Sales632.26436.17385.7827.47Price / CashN/A168.6838.1617.54Price / Book1.333.956.934.60Net Income-$19.03M-$71.95M$3.20B$1.02B7 Day PerformanceN/A-3.76%-2.30%0.37%1 Month Performance3.04%-10.33%2.86%-2.45%1 Year Performance9.72%-27.15%10.66%5.03% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics0.982 of 5 stars$2.37-0.8%$6.50+174.3%+3.0%$164.39M$260,000.00-0.896News CoverageCRMDCorMedix2.6347 of 5 stars$10.77-1.3%$16.00+48.6%+61.3%$653.49M$12.26M-13.3030Earnings ReportAnalyst ForecastOptions VolumeNews CoverageIMNMImmunome1.9533 of 5 stars$8.15-0.4%$25.50+212.9%-71.5%$650.18M$10.13M-1.0040Insider TradeNews CoverageGap UpABUSArbutus Biopharma1.4613 of 5 stars$3.39+3.4%$5.50+62.2%+25.8%$642.38M$6.74M-7.8890Earnings ReportAnalyst RevisionNews CoverageBCYCBicycle Therapeutics1.9498 of 5 stars$9.20+1.3%$29.14+216.8%-62.6%$636.66M$35.28M-2.80240High Trading VolumeDNTHDianthus Therapeutics1.3915 of 5 stars$19.41-0.4%$54.33+179.9%-35.1%$623.55M$6.24M-7.7680KURAKura Oncology4.3102 of 5 stars$7.65-2.4%$25.50+233.3%-66.3%$617.78M$53.88M-3.24130Analyst UpgradeCDXCChromaDex4.4964 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Analyst ForecastKALVKalVista Pharmaceuticals4.3335 of 5 stars$12.25+3.0%$23.80+94.3%+11.5%$609.02MN/A-3.37100Analyst ForecastNews CoverageMGTXMeiraGTx4.777 of 5 stars$7.69+1.7%$24.50+218.6%+19.0%$606.40M$33.28M-6.36300Analyst RevisionVALNValneva1.8479 of 5 stars$7.43+3.6%$16.00+115.3%-8.9%$603.77M$158.54M-57.15700Short Interest ↑Gap Up Remove Ads Related Companies and Tools Related Companies CRMD Alternatives IMNM Alternatives ABUS Alternatives BCYC Alternatives DNTH Alternatives KURA Alternatives CDXC Alternatives KALV Alternatives MGTX Alternatives VALN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
